Brand and generic erectile-dysfunction medications can contain the same active ingredient, but a valid comparison starts with FDA-approved product identity rather than a familiar trademark. Viagra contains sildenafil and Cialis contains tadalafil. Levitra was a vardenafil brand, while Staxyn was a separately labeled vardenafil orally disintegrating tablet. A generic approved in the same active ingredient, dosage form and strength may be therapeutically equivalent under FDA standards; a product with a different ingredient or form is not automatically a substitute.
FDA evaluates generic applications and identifies therapeutic-equivalence determinations in the Orange Book where applicable. Equivalent approved medicines may differ in appearance or inactive ingredients without being clinically inferior. Conversely, a foreign-branded product or a supplement cannot establish U.S. approval by pointing to an identical ingredient name on a sales page. FDA marketing status, pharmacy stock and product substitution are separate facts.
This page compares those principles across ED medicines. For an ingredient-specific brand discussion, see Viagra versus generic sildenafil and Cialis versus generic tadalafil. The generic vardenafil guide covers the discontinued-brand context separately.
The table focuses on the marketed product family and required equivalence checks, not on current prices or a promise that every historic brand remains on U.S. pharmacy shelves. Every individual product needs an actual approval and label history.
Avanafil provides another useful example: Stendra is a branded avanafil product, and FDA-listed generic avanafil entries now exist. Approval records do not necessarily guarantee current dispensing availability for either option.
| Active ingredient | Brand reference or history | Generic/substitution check |
|---|---|---|
| Sildenafil for ED | Viagra | Verify approved sildenafil ED tablet, strength, dosage form and equivalence |
| Tadalafil for ED | Cialis | Verify corresponding approved tadalafil tablet and indication/regimen |
| Vardenafil film-coated | Levitra brand discontinued in U.S. | Review active approved generic tablet records separately |
| Vardenafil ODT | Staxyn brand discontinued in U.S. | Assess approved ODT separately; not interchangeable with film-coated tablets |
| Avanafil | Stendra | Review separately approved generic avanafil tablets and actual availability |
For products FDA regards as therapeutically equivalent, regulatory standards address identity of active ingredient, strength, route, dosage form, quality, bioequivalence and expected clinical effect under labeled use. Equivalent approved generics are not categorically weaker or less safe than brand products merely because their packaging or tablet appearance differs.
Orange Book ratings are product-specific. Two medicines that treat ED but contain different active substances are not therapeutic equivalents to each other just because both are PDE5 inhibitors. Pharmacists and prescribers apply these determinations alongside applicable state substitution rules.
For eligible multisource prescription drugs, the Orange Book identifies FDA therapeutic-equivalence evaluations using product-specific codes. An AB rating generally indicates that the product meets the relevant bioequivalence requirements in its applicable pharmaceutical-equivalence grouping; AB1, AB2 and related suffixes can distinguish different reference-product groupings. A pharmacist must consider the exact product, dosage form, strength, route, and relevant code instead of treating every tablet with the same ingredient as interchangeable.
FDA approval and a therapeutic-equivalence rating answer related but different questions. An NDC is a labeling identifier rather than an approval or equivalence certificate, while the FDA application and Orange Book record document regulatory status. A code cannot authorize swapping an oral ED tablet for a different active ingredient, a non-equivalent formulation, or a product whose substitution is restricted by the prescription or state law.
Vardenafil 10 mg ODT and vardenafil 10 mg film-coated tablets illustrate the danger of relying on a shared ingredient and number. They are different drug products with distinct labeling and should not be automatically substituted. The historical Staxyn brand label does not resolve which current generic ODT product is available.
The same principle applies when comparing oral tablets to unapproved jelly, chewable or other foreign-marketed forms. FDA approval belongs to specific applications and products. See the ODT formulation guide for the practical distinction.
Sildenafil products have separate U.S.-approved uses and presentations for erectile dysfunction and pulmonary arterial hypertension. Product names, dosage forms and instructions must be matched to the prescription’s indication. A PAH label cannot simply be substituted for an ED product guide.
Tadalafil has separate labeled ED, BPH and combined ED/BPH contexts, with different prescribing frameworks. Pharmacy verification therefore includes not just active ingredient and milligrams, but also the product and its intended regimen.
The original U.S. Levitra and Staxyn brand presentations have been discontinued. That does not mean the ingredient vardenafil or every corresponding generic formulation disappeared from FDA approval records. A generic may be listed separately, and whether it is currently stocked still needs a pharmacy check.
Do not translate a historical brand name into a guaranteed current retail offer. The Levitra history page and the Staxyn history page explain the individual products without encouraging purchases of discontinued brands.
Tablet shape, imprint, color and inactive ingredients may differ among FDA-approved manufacturers. Those variations do not by themselves establish worse efficacy or a counterfeit product, but a mismatch with the actual dispensed pharmacy label warrants a pharmacist check.
Patients with a known excipient sensitivity or uncertainty about a new appearance should identify the manufacturer/labeler and ask the pharmacist to confirm the exact NDC and formulation. An NDC is a product identifier, not standalone proof of FDA approval or evidence that stock exists.
An India-market brand containing sildenafil or tadalafil does not become an FDA-approved U.S. generic merely because the active ingredient is familiar. A company may market several strengths and combination products under related names, so composition needs product-specific verification.
Foreign regulatory status, exact company role, composition and approval are distinct claims. The Indian sildenafil brands directory and Indian tadalafil brands directory treat those market identities separately without suggesting unapproved cross-border fulfillment.
Brand-versus-generic decisions may affect cost, but actual patient payment depends on the product, prescribed quantity, pharmacy, insurance claim, dispensing charges and fulfillment terms. A generic might offer another option, yet no fixed savings or universally cheaper product can be promised.
After medical review, ask a licensed pharmacy for a complete current quote for the precise prescribed item and an allowed equivalent if applicable. The ED cost comparison focuses on durable variables rather than dated numbers.
Ask the pharmacist: Which approved application and product are being dispensed? Does the active ingredient, strength, route and form match the prescription? Does the Orange Book identify a relevant therapeutic-equivalence code, such as AB or a reference-specific AB suffix? Does the prescriber permit substitution, and do local laws impose additional conditions?
Confirm the actual package label and counseling directions before use. If a prescriber has specified a medically necessary product, do not override that decision based solely on a checkout price. Brand recognition is not a substitute for verifying the pharmacy and product.
Sildenafil, tadalafil, vardenafil and avanafil may differ in labeled timing, interactions, indications and administration directions. The decision among different active substances is a clinical treatment choice, not a routine brand-to-generic substitution. Nitrates and riociguat remain major contraindications for oral PDE5 ED treatment.
Use the ED treatment overview if the question involves broader therapies, or the prescription assessment guide for legitimate medical evaluation. Then assess brand or equivalent generic dispensing within the selected treatment.
Many specific generic ED products are FDA-approved. Check the precise application and formulation; an ingredient name, NDC or foreign seller listing alone does not establish U.S. approval or therapeutic equivalence.
An FDA product classified as therapeutically equivalent is expected to have the same clinical effect and safety profile under labeled conditions.
Yes. Approved equivalents may differ in inactive ingredients and appearance, subject to applicable quality standards.
Approved generic vardenafil tablet products are separately regulated. The historic Levitra brand itself was discontinued in the U.S.
No automatic interchangeability should be assumed between those formulations.
Not necessarily. U.S. approval requires a specific product application and cannot be inferred from the ingredient name.
No. Brand status alone does not establish superior effectiveness compared with an appropriately approved therapeutically equivalent generic.
No. Switching from one active ingredient to another is a clinical treatment decision, not an ordinary same-drug generic substitution.